New antithrombotic drugs for the treatment of venous thromboembolism;Les nouveaux anticoagulants dans la maladie thrombo-embolique veineuse

Revue des Maladies Respiratoires

Volumn 28, Issue 8, 2011, Pages 1008-1016

  Bertoletti, L ^a,b   Mismetti, P ^a,b  

^a University Jean Monnet of Saint Etienne EA3065   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Antithrombotic therapy; Dabigatran; Pulmonary embolism; Renal insufficiency; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; EDOXABAN; HEPARIN; HEPARIN DERIVATIVE; PROTHROMBIN; RIVAROXABAN; VITAMIN K GROUP;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

EID: 84055211897     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-9. (Pubitemid 40216038)
2. Buller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357:1094-104. (Pubitemid 47443214)
3. Buller HR, Cohen AT, Davidson B, et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007;357:1105-12. (Pubitemid 47443215)
4. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008;371:315-21.
5. Buller HR, Destors JM, Gallus AS, et al. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX study): safety, efficacy, and reversibility by avidin. Blood 2008;112:32 [ASH annual meeting abstracts].
6. The Equinox investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011;9:92-9.
7. Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010;8:722-9.
8. Quan ML, Lam PY, Han Q, et al. Discovery of 1-(3'-aminobenzisoxazol-5'- yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl) imidazol-1-yl]phenyl]-1Hpyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2005;48:1729-44. (Pubitemid 40396307)
9. Lassen MR, Davidson BL, Gallus A, et al. A phase II randomized double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery-on behalf of the razaxaban investigators. Blood 2003;102:15A [ASH annual meeting abstracts].
10. Mismetti P, Laporte S. [Dabigatran: clinical pharmacology]. Ann Fr Anesth Reanim 2009;28:S8-14.
11. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75. (Pubitemid 351930851)
12. Lassen MR, AgenoW, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86. (Pubitemid 351930852)
13. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep vein thrombosis) study. Circulation 2007;116:180-7. (Pubitemid 47057524)
14. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112:2242-7.
15. The EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510, doi:10.1056/NEJMoa1007903.
16. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81.
17. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.
18. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15.
19. Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6:1313-8. (Pubitemid 352016310)
20. Eriksson H, Wahlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003:41-7.
21. Eriksson H, Lundstrom T, Wahlander K, et al. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thromb Haemost 2005;94:522-7. (Pubitemid 41300846)
22. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12. (Pubitemid 37315007)
23. Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009;86:139-46.
24. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59. (Pubitemid 350260888)
25. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95. (Pubitemid 351508116)
26. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallelgroup, single-centre study. Clin Pharmacokinet 2010;49: 259-68.
27. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004;2:1573-80. (Pubitemid 40186173)
28. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-11. (Pubitemid 41647122)
29. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5: 2178-85. (Pubitemid 47617868)
30. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24: 1-9.
31. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet 2007;370:949-56. (Pubitemid 47393577)
32. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol 2007;100:1419-26. (Pubitemid 47576022)
33. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
34. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
35. Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 2010;8: 621-6.